Roivant Sciences (NASDAQ:ROIV) Given New $42.00 Price Target at Guggenheim

Roivant Sciences (NASDAQ:ROIV) had its price objective boosted by Guggenheim from $36.00 to $42.00 in a report issued on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on ROIV. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup upped their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, HC Wainwright raised their price target on Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.77.

Roivant Sciences Stock Up 3.5%

NASDAQ ROIV opened at $36.34 on Friday. The company has a market capitalization of $26.14 billion, a P/E ratio of -68.57 and a beta of 1.12. Roivant Sciences has a 12-month low of $10.90 and a 12-month high of $37.00. The firm has a 50-day moving average price of $33.13 and a two-hundred day moving average price of $29.46.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. The trade was a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This represents a 5.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,055,913 shares of company stock worth $69,639,633 over the last three months. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG lifted its stake in Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after purchasing an additional 15,645,836 shares during the last quarter. Morgan Stanley grew its stake in shares of Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 365.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after buying an additional 8,621,567 shares in the last quarter. Norges Bank acquired a new position in shares of Roivant Sciences during the fourth quarter worth $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences in the 4th quarter valued at $76,272,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences News Summary

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.